Bicara Therapeutics’ (BCAX) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Bicara Therapeutics (NASDAQ:BCAX) in a research report report published on Thursday,Benzinga reports. Cantor Fitzgerald currently has a $13.01 price target on the stock.

BCAX has been the subject of several other research reports. Wedbush reaffirmed an “outperform” rating and set a $31.00 target price on shares of Bicara Therapeutics in a research note on Wednesday, February 12th. HC Wainwright raised their price objective on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, January 27th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $36.50.

Bicara Therapeutics Stock Down 7.0 %

Shares of BCAX stock opened at $12.42 on Thursday. The stock’s 50-day moving average is $13.19. Bicara Therapeutics has a 1-year low of $11.10 and a 1-year high of $28.09.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in BCAX. Spire Wealth Management purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $32,000. Legal & General Group Plc purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $33,000. Summit Investment Advisors Inc. purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $35,000. Finally, Virtus ETF Advisers LLC purchased a new stake in shares of Bicara Therapeutics during the 4th quarter worth approximately $69,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.